| Literature DB >> 30312871 |
Brittany E Jewell1, Mo Liu2, Linchao Lu3, Ruoji Zhou1, Jian Tu4, Dandan Zhu2, Zijun Huo5, An Xu2, Donghui Wang6, Helen Mata3, Weidong Jin3, Weiya Xia7, Pulivarthi H Rao3, Ruiying Zhao2, Mien-Chie Hung8, Lisa L Wang9, Dung-Fang Lee10.
Abstract
The DNA helicase RECQL4 is known for its roles in DNA replication and repair. RECQL4 mutations cause several genetic disorders including Rothmund-Thomson syndrome (RTS), characterized by developmental defects and predisposition to osteosarcoma. Here we reprogrammed fibroblasts with a heterozygous RECQL4 mutation (c.1878 + 32_1878 + 55del24) to induced pluripotent stem cells (iPSCs). These iPSCs are pluripotent and are able to be differentiated into all three germ layers, providing a novel tool to further interrogate the role of RECQL4 DNA helicase in vitro.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30312871 PMCID: PMC6317900 DOI: 10.1016/j.scr.2018.10.003
Source DB: PubMed Journal: Stem Cell Res ISSN: 1873-5061 Impact factor: 2.020
Fig. 1.Generation and characterization of FCP351G iPSCs. (A) Sanger sequence of RECQL4 Exons 11-12 depicting the deletion found in FCP351 fibroblasts and verified by Sanger sequencing (see chromatogram) in FCP351G iPSCs. (B) Cell morphology (left panel) and alkaline phosphatase staining (right panel) of the FCP351G line. Scale bar, 250 μm (left) and 100 μm (right). (C) PCR detection of exogenous OCT4, SOX2, KLF4 and c-MYC in FCP351G iPSCs. (D) Mycoplasma PCR assay in FCP351G iPSCs.(E) Immunofluorescence staining of pluripotency factor NANOG and hESC surface markers (SSEA4 and TRA-1-81) in the FCP351G line. Scale bar, 75 μm. (F) qRT-PCR assay for the expression of endogenous pluripotency genes (NANOG, SOX2, OCT4, DPPA4, REX1, and TERT) in the FCP351G iPSCs. (G) A representative G-banded karyotype from iPSCs (FCP351G) showing 46, XX. (H) In vivo teratoma assay of the FCP351G iPSCs. Scale bar, 50 μm.
Characterization and validation.
| Classification | Test | Result | Data |
|---|---|---|---|
| Morphology | Photography | Normal | |
| Phenotype | Qualitative analysis immunocytochemistry | Positive staining for NANOG, SSEA and TRA-1-81 | |
| Quantitative analysis RT-qPCR | Expression of pluripotency markers equivalent or greater than H1 embryonic stem cells | ||
| Genotype | Karyotype (G-banding) and resolution | 46; XX, Resolution 400 | |
| Identity | Microsatellite PCR (mPCR) OR | DNA Profiling not performed | N/A |
| STR analysis | 14 sites tested, all sites match | data available with authors | |
| Mutation analysis (IF APPLICABLE) | Sequencing | Heterozygous | |
| Southern Blot OR WGS | N/A | N/A | |
| Microbiology and virology | Mycoplasma | Negative | |
| Differentiation potential | Teratoma formation | Differentiation to all three germ layers confirmed by H&E Staining | |
| Donor screening (OPTIONAL) | N/A | N/A | N/A |
| Genotype additional info | N/A | N/A | N/A |
| (OPTIONAL) | N/A | N/A | N/A |
Reagents details.
| Antibodies used for immunocytochemistry | |||
|---|---|---|---|
| Antibody | Dilution | Company Cat # and RRID | |
| Pluripotency Markers | Goat anti-NANOG | 1:500 | R and D Systems Cat# AF1997 RRID:AB_355097 |
| Pluripotency Markers | anti-SSEA4 PE-conjugated | 1:600 | R and D Systems FA1435P-025 |
| Pluripotency Markers | Mouse anti-TRA-1-85 Alexa Fluor 555-conjugated | 1:600 | R and D Systems Cat# FAB3195A RRID:AB_663789 |
| Secondary antibodies | Donkey Anti-Goat IgG (Alexa Fluor488 conjugate) | 1:500 | Jackson ImmunoResearch Labs Cat# 705–545-003 RRID:AB_2340428 |
| Resource Table. | |
|---|---|
| Unique stem cell line identifier | CDMLi002-A |
| Alternative name(s) of stem cell line | FCP351G |
| Institution | McGovern Medical School, The University of Texas Health Science Center Houston |
| Contact information of distributor | Dung-Fang Lee |
| Type of cell line | iPSCs |
| Origin | Human |
| Additional origin info | Age: 24 years |
| Ethnicity if known: not Hispanic, White | |
| Cell source | fibroblast |
| Clonality | clonal |
| Method of reprogramming | Sendai virus |
| Genetic modification | N/A |
| Type of modification | Germline mutation |
| Associated disease | Rothmund-Thomson syndrome |
| Gene/locus | |
| Method of modification | N/A |
| Name of transgene or resistance | N/A |
| Inducible/constitutive system | N/A |
| Date archived/stock date | 3/31/2018 |
| Cell line repository/bank | N/A |
| Ethical approval | The Molecular Basis of Familial Cancer Predisposition Syndromes (IRB# H-7207) provide by Baylor College of Medicine |